[{"address1": "6200 Lookout Road", "city": "Boulder", "state": "CO", "zip": "80301", "country": "United States", "phone": "720 647 8519", "website": "https://www.enliventherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.", "fullTimeEmployees": 65, "companyOfficers": [{"maxAge": 1, "name": "Mr. Samuel S. Kintz M.B.A.", "age": 38, "title": "Co-Founder & Head of Pipeline", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 973800, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Joseph P. Lyssikatos Ph.D.", "age": 60, "title": "Co-Founder & Chief Scientific Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 709400, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Helen Louise Collins M.D.", "age": 62, "title": "Chief Medical Officer", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 746400, "exercisedValue": 0, "unexercisedValue": 4612248}, {"maxAge": 1, "name": "Mr. Richard A. Fair", "age": 56, "title": "CEO, President & Director", "yearBorn": 1969, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Anish  Patel Pharm.D.", "age": 45, "title": "Co-Founder & COO", "yearBorn": 1980, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin  Hohl", "age": 36, "title": "CFO & Head of Corporate Development", "yearBorn": 1989, "fiscalYear": 2024, "totalPay": 488500, "exercisedValue": 0, "unexercisedValue": 1212737}, {"maxAge": 1, "name": "Dr. Galya D. Blachman Esq., Ph.D.", "age": 48, "title": "Chief Legal Officer & Head of Business Development", "yearBorn": 1977, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 5, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1768176000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 25.17, "open": 25.34, "dayLow": 24.82, "dayHigh": 27.4628, "regularMarketPreviousClose": 25.17, "regularMarketOpen": 25.34, "regularMarketDayLow": 24.82, "regularMarketDayHigh": 27.4628, "payoutRatio": 0.0, "beta": 1.2, "forwardPE": -11.270042, "volume": 1230122, "regularMarketVolume": 1230122, "averageVolume": 920900, "averageVolume10days": 2230740, "averageDailyVolume10Day": 2230740, "bid": 19.65, "ask": 26.81, "bidSize": 2, "askSize": 3, "marketCap": 1585166720, "fiftyTwoWeekLow": 13.3, "fiftyTwoWeekHigh": 29.98, "allTimeHigh": 250.84, "allTimeLow": 3.896, "fiftyDayAverage": 19.635, "twoHundredDayAverage": 19.75725, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1108091776, "profitMargins": 0.0, "floatShares": 37504537, "sharesOutstanding": 59347317, "sharesShort": 8312949, "sharesShortPriorMonth": 7996827, "sharesShortPreviousMonthDate": 1764288000, "dateShortInterest": 1767139200, "sharesPercentSharesOut": 0.1401, "heldPercentInsiders": 0.08239, "heldPercentInstitutions": 1.03151, "shortRatio": 10.74, "shortPercentOfFloat": 0.19940001, "impliedSharesOutstanding": 59347317, "bookValue": 8.034, "priceToBook": 3.32462, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -97207000, "trailingEps": -1.81, "forwardEps": -2.37, "enterpriseToEbitda": -9.896, "52WeekChange": 0.14409089, "SandP52WeekChange": 0.14799047, "quoteType": "EQUITY", "currentPrice": 26.71, "targetHighPrice": 52.0, "targetLowPrice": 33.0, "targetMeanPrice": 41.375, "targetMedianPrice": 40.0, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 477564992, "totalCashPerShare": 8.047, "ebitda": -111972000, "totalDebt": 490000, "quickRatio": 32.598, "currentRatio": 32.948, "debtToEquity": 0.103, "returnOnAssets": -0.17623, "returnOnEquity": -0.25429, "freeCashflow": -45616124, "operatingCashflow": -71666000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ELVN", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1768608285, "regularMarketTime": 1768597202, "shortName": "Enliven Therapeutics, Inc.", "longName": "Enliven Therapeutics, Inc.", "exchange": "NMS", "messageBoardId": "finmb_693128628", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "regularMarketChangePercent": 6.11839, "regularMarketPrice": 26.71, "postMarketPrice": 26.8032, "postMarketChange": 0.09320068, "regularMarketChange": 1.54, "regularMarketDayRange": "24.82 - 27.4628", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 920900, "fiftyTwoWeekLowChange": 13.409999, "fiftyTwoWeekLowChangePercent": 1.0082706, "fiftyTwoWeekRange": "13.3 - 29.98", "fiftyTwoWeekHighChange": -3.2700005, "fiftyTwoWeekHighChangePercent": -0.10907273, "fiftyTwoWeekChangePercent": 14.409089, "earningsTimestampStart": 1763067600, "earningsTimestampEnd": 1763067600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.81, "epsForward": -2.37, "epsCurrentYear": -1.8, "priceEpsCurrentYear": -14.838889, "fiftyDayAverageChange": 7.074999, "fiftyDayAverageChangePercent": 0.36032587, "twoHundredDayAverageChange": 6.9527493, "twoHundredDayAverageChangePercent": 0.35190874, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.0 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1584019800000, "postMarketChangePercent": 0.34893554, "displayName": "Enliven Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-01-17"}]